|1.||Gan, Tong J: 16 articles (12/2014 - 04/2002)|
|2.||Habib, Ashraf S: 15 articles (08/2014 - 04/2003)|
|3.||White, Paul F: 14 articles (07/2012 - 06/2002)|
|4.||Fujii, Yoshitaka: 12 articles (12/2011 - 05/2002)|
|5.||Morrow, Gary R: 9 articles (03/2014 - 03/2002)|
|6.||Chan, Alexandre: 8 articles (01/2015 - 03/2008)|
|7.||Molassiotis, Alexander: 8 articles (05/2014 - 04/2002)|
|8.||Roscoe, Joseph A: 8 articles (07/2012 - 03/2002)|
|9.||Hesketh, Paul J: 8 articles (05/2012 - 10/2002)|
|10.||Navari, Rudolph M: 7 articles (01/2015 - 01/2004)|
07/01/2012 - "Clinical efficacy of anti-emetics is highly correlated with efficacy in the ferret emesis model, suggesting rolapitant is a viable clinical candidate for this indication."
08/01/2008 - "Experimental data provide evidence for efficacy against a wide range of peripheral and central emetic stimuli and clinical trials confirm that neurokinin-1 antagonists have significantly higher efficacy against vomiting than all other antiemetics, with relative risk reductions of over 50%. "
05/01/2003 - "Available data indicates that the 5-HT3-receptor antagonists are at least as good as conventional antiemetics in controlling delayed-onset emesis, and that their efficacy in this setting may be improved by the addition of a corticosteroid. "
03/01/1987 - "Combination anti-emesis has further improved control rates and new schedules of currently available anti-emetics are now proving their worth. "
06/01/2007 - "These findings further suggest that the least shrew can be utilized as a versatile and inexpensive small animal model to rapidly screen the efficacy of investigational antiemetics for the prevention of radiation-induced emesis."
01/01/1993 - "The use of 5-HT3-antagonists as antiemetics has dramatically improved the quality of life during treatment by reducing the frequency of nausea to only 12.5%. "
08/01/2008 - "However, efficacy against nausea does not appear to be superior to other antiemetics, so that composite outcomes that are driven by nausea (e.g. "
03/01/2007 - "Combining antiemetics with other non-pharmacological treatments may prove more effective in decreasing nausea than antiemetics alone. "
01/01/2009 - "Of the 145 nauseous patients only 25% felt that antiemetics had helped them and 34% would have liked additional treatment, although the nausea intensity was mild in 72%. "
03/01/2004 - "An understanding of the pathophysiology of nausea and the mechanisms of antiemetics can help family physicians improve the cost-effectiveness and efficacy of therapy. "
|3.||Postoperative Nausea and Vomiting (PONV)
05/01/1998 - "The willingness-to-pay technique was used to value the intangible benefits, such as relief from anxiety and discomfort, resulting from a reduction in postoperative emesis in children; anxiety and discomfort are currently excluded from most cost-effectiveness studies of antiemetic agents. "
12/01/2002 - "To effectively prevent and treat PONV, it is important to understand the factors implicated in PONV, the mechanisms of PONV, the pharmacology of the antiemetic agents, and the nonpharmacologic measures that have been shown to be effective. "
02/01/2011 - "Combination antiemetic therapy often is effective for preventing PONV in patients undergoing LC, and combinations of antiemetics targeting different sites of activity may be more effective than monotherapy. "
09/01/2003 - "Prophylaxis with a combination of antiemetic drugs is more effective in prevention of PONV."
10/01/1996 - "Overall incidence of PONV was determined for all groups and the relative efficacy of the three antiemetic agents assessed. "
05/01/2000 - "In advanced cancer patients with inoperable bowel obstruction, the administration of antisecretive and antiemetic drugs has proved to be effective in controlling gastrointestinal symptoms caused by bowel obstruction. "
01/01/2012 - "Medical and behavioral interventions may help to alleviate the negative consequences of chemotherapeutic treatment in patients with gynecologic cancers treated with suboptimal antiemetics."
01/01/2002 - "Several classes of antiemetic agents exist to combat these side effects, though the 5-HT(3)-receptor antagonists have become the first-line treatment choice for many cancer patients and are considered the "gold standard" in antiemetic therapy. "
08/15/1994 - "Smoking prevention and cessation programs could lead to 7.2 million fewer smokers; application of cancer screening programs might result in 45,000 additional 5-year cancer survivors each year; and behavioral programs could lead to improved quality of life in 150,000 patients per year who experience treatment side effects despite the use of antiemetics. "
01/01/1980 - "The clinical efficacy of antiemetic drugs was tested in cancer patients who were given a placebo and two antiemetic drugs alone and in combination according to random sequences. "
11/01/2015 - "Patients in the intervention group had lower pain score and took less antiemetics. "
04/01/2013 - "There was no difference in visual pain scores or antiemetics given. "
11/01/2011 - "Also, the usage of rescue antiemetics and pain intensity were recorded. "
06/01/2009 - "Requirements for analgesic and antiemetic drugs, intensity of pain, intestinal function recovery, mean levels of postoperative satisfaction, postoperative complications, and quality-of-life scores did not differ between the two groups. "
07/01/2007 - "Requests and doses of antiemetics, postoperative verbal numerical pain scores and length of hospital stay were similar between the two groups. "
|3.||Serotonin (5 Hydroxytryptamine)
|9.||Analgesics (Analgesic Drugs)
|1.||Drug Therapy (Chemotherapy)
|3.||Gynecologic Surgical Procedures (Gynecologic Surgery)